Rigosertib sodium (DrugBank: Rigosertib)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
36 | Epidermolysis bullosa | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04177498 (ClinicalTrials.gov) | January 1, 2021 | 7/11/2019 | Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | A Pilot, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma | Recessive Dystrophic Epidermolysis Bullosa | Drug: Rigosertib Sodium;Other: Quality-of-Life Assessment | Thomas Jefferson University | Onconova Therapeutics, Inc. | Not yet recruiting | 18 Years | 79 Years | All | 6 | Early Phase 1 | United States |